NCT06413433: Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
- State
- Under way
- Phase
- Phase 3
- People
- 450 planned
- Started
- 26 Apr 2024
- Primary completion
- Dec 2026
- Arms
- Solriamfetol 150 mg, Solriamfetol 300 mg
- Results
- None posted
- 26 Apr 2024: Trial started
- 14 May 2024: Trial registered